Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care

Authors: Rui Tato Marinho, António Costa, Teodomiro Pires, Helena Raposo, Carlos Vasconcelos, Cristina Polónia, Joaquim Borges, Mariana Soares, Graça Vilar, Ana Maria Nogueira, on behalf of the LIGUE-C Investigators

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

HCV treatment among people who inject drugs (PWID) is low. Education programs may be suitable strategies to improve patients’ knowledge about their condition and to overcome barriers to access treatment.

Methods

The Health Educational Program (HEP) consisted of patient workshops and educational videos and leaflets, and healthcare professionals’ workshops. HEP was implemented at seven substance dependence treatment centers (STDC) in Portugal. The study comprised two cross-sectional evaluations conducted before and after HEP. At both evaluations, adult patients with confirmed HCV diagnosis and registered in the STDC were consecutively included. For patients that completed both evaluations, the overall knowledge score were calculated and compared with McNemar test. Linear regression modelling was used to evaluate factors associated with baseline knowledge. Rates of referral and attendance to referral specialist, treatment proposal, initiation and retention at both evaluations were also compared with McNemar test.

Results

Overall, 504 patients with chronic hepatitis C were included: 78 % male, mean age 42.3 ± 6.6 years, 14 % school education ≤ 4 years, disease duration 11.0 ± 6.0 years and 26 % HIV co-infected. A higher baseline knowledge was independently associated with educational level ≥ 10 years (regression coefficient [B] =15.13, p < 0.001), current use of intravenous drugs (B = 7.99, p = 0.038), previous referral for treatment (B = 4.26, p = 0.008) and previous HCV treatment (B = 5.40, p = 0.003). Following HEP, mean knowledge score increased from 69 % to 79 % (p < 0.001). The rate of patient referral to a liver specialist increased from 56.2 % to 67.5 % (p < 0.001).

Conclusions

An HEP conducted at STDCs improved significantly patient knowledge about hepatitis C, even among patients with a high baseline knowledge. The HEP has also increased the rate of referral to the liver specialist and showed a great potential to support healthcare professionals in managing HCV. Education programs may promote treatment access among PWID, a population that represents the majority of HCV infected patients.
Appendix
Available only for authorised users
Literature
2.
go back to reference Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMed Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMed
3.
go back to reference Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631–40.CrossRefPubMed Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631–40.CrossRefPubMed
4.
go back to reference Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014;142(2):270–86.CrossRefPubMed Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014;142(2):270–86.CrossRefPubMed
5.
go back to reference Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31 Suppl 2:30–60.CrossRefPubMed Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31 Suppl 2:30–60.CrossRefPubMed
6.
go back to reference Anjo J, Café A, Carvalho A, Doroana M, Fraga J, Gíria J, et al. [O impacto da hepatite C em Portugal]. J Port Gastrenterol. 2014;21(2):44–54. Anjo J, Café A, Carvalho A, Doroana M, Fraga J, Gíria J, et al. [O impacto da hepatite C em Portugal]. J Port Gastrenterol. 2014;21(2):44–54.
7.
go back to reference Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 1:5–33.CrossRefPubMed Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 1:5–33.CrossRefPubMed
8.
go back to reference Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol. 2013;19(44):7846–51.CrossRefPubMedPubMedCentral Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol. 2013;19(44):7846–51.CrossRefPubMedPubMedCentral
9.
go back to reference Lazarus JV, Sperle I, Maticic M, Wiessing L. A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect Dis. 2014;14 Suppl 6:S16.CrossRefPubMed Lazarus JV, Sperle I, Maticic M, Wiessing L. A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect Dis. 2014;14 Suppl 6:S16.CrossRefPubMed
10.
go back to reference Munoz-Plaza CE, Strauss S, Astone-Twerell J, Jarlais DD, Gwadz M, Hagan H, et al. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy. 2008;19(1):71–8.CrossRefPubMed Munoz-Plaza CE, Strauss S, Astone-Twerell J, Jarlais DD, Gwadz M, Hagan H, et al. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy. 2008;19(1):71–8.CrossRefPubMed
11.
go back to reference O'Brien S, Day C, Black E, Dolan K. Injecting drug users' understanding of hepatitis C. Addict Behav. 2008;33(12):1602–5.CrossRefPubMed O'Brien S, Day C, Black E, Dolan K. Injecting drug users' understanding of hepatitis C. Addict Behav. 2008;33(12):1602–5.CrossRefPubMed
12.
go back to reference Surjadi M, Torruellas C, Ayala C, Yee Jr HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56(1):213–9.CrossRefPubMed Surjadi M, Torruellas C, Ayala C, Yee Jr HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56(1):213–9.CrossRefPubMed
13.
go back to reference Maticic M, Videcnik Zorman J, Gregorcic S, Schatz E, Lazarus JV. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infect Dis. 2014;14(6):1–9. Maticic M, Videcnik Zorman J, Gregorcic S, Schatz E, Lazarus JV. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infect Dis. 2014;14(6):1–9.
14.
go back to reference Velosa J, Caldeira L, Lopes AI, Guerreiro L, Marinho R. Recomendações para a terapêutica da hepatite C. J Port Gastrenterol. 2012;19(3):133–9.CrossRef Velosa J, Caldeira L, Lopes AI, Guerreiro L, Marinho R. Recomendações para a terapêutica da hepatite C. J Port Gastrenterol. 2012;19(3):133–9.CrossRef
15.
go back to reference Direção-Geral da Saúde. [Tratamento da Hepatite C Crónica no Adulto. Norma n° 011/2012 de 16/12/2012 atualizada a 30/04/2015]. Lisboa: Direção-Geral da Saúde; 2015. Direção-Geral da Saúde. [Tratamento da Hepatite C Crónica no Adulto. Norma n° 011/2012 de 16/12/2012 atualizada a 30/04/2015]. Lisboa: Direção-Geral da Saúde; 2015.
16.
go back to reference Leite RB. Consensus for the integrated management of hepatitis C in Portugal. BMC Infect Dis. 2014;14 Suppl 6:S9. S.CrossRefPubMed Leite RB. Consensus for the integrated management of hepatitis C in Portugal. BMC Infect Dis. 2014;14 Suppl 6:S9. S.CrossRefPubMed
17.
go back to reference Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, et al. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat. 2016;23 Suppl 1:1–12.CrossRefPubMed Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, et al. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat. 2016;23 Suppl 1:1–12.CrossRefPubMed
18.
go back to reference Birkhead GS, Klein SJ, Candelas AR, O'Connell DA, Rothman JR, Feldman IS, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy. 2007;18(5):417–25.CrossRefPubMed Birkhead GS, Klein SJ, Candelas AR, O'Connell DA, Rothman JR, Feldman IS, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy. 2007;18(5):417–25.CrossRefPubMed
19.
go back to reference Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013;33(7):999–1007.CrossRefPubMedPubMedCentral Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013;33(7):999–1007.CrossRefPubMedPubMedCentral
20.
go back to reference North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2013;35(2):122–8.CrossRefPubMed North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2013;35(2):122–8.CrossRefPubMed
21.
go back to reference Sarmento ECR, Valente C, Ramos JP, Almeida JR, Marinho RT, Branco T, et al. [Hepatitis C in drug addicts: access and treatment compliance]. Acta Med Port. 2011;24 Suppl 2:483–92. Sarmento ECR, Valente C, Ramos JP, Almeida JR, Marinho RT, Branco T, et al. [Hepatitis C in drug addicts: access and treatment compliance]. Acta Med Port. 2011;24 Suppl 2:483–92.
22.
go back to reference Bonner JE, Barritt AS, Fried MW, Evon DM. Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Dig Dis Sci. 2012;57(6):1439–44.CrossRefPubMedPubMedCentral Bonner JE, Barritt AS, Fried MW, Evon DM. Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Dig Dis Sci. 2012;57(6):1439–44.CrossRefPubMedPubMedCentral
23.
go back to reference Sun X, Patnode CD, Williams C, Senger CA, Kapka TJ, Whitlock EP. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness. Rockville: Agency for Healthcare Research and Quality (US); 2012. Sun X, Patnode CD, Williams C, Senger CA, Kapka TJ, Whitlock EP. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness. Rockville: Agency for Healthcare Research and Quality (US); 2012.
27.
go back to reference Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE. 2014;9(7):e103345.CrossRefPubMedPubMedCentral Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE. 2014;9(7):e103345.CrossRefPubMedPubMedCentral
28.
go back to reference van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMed van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMed
29.
go back to reference The VA Hepatitis C Resource Center Program and the National Clinical Public Health Program. In: Veterans Health Administration, editor. Managing Side Effects of Hepatitis C Treatment. U.S: Department of Veterans Affairs; 2007. The VA Hepatitis C Resource Center Program and the National Clinical Public Health Program. In: Veterans Health Administration, editor. Managing Side Effects of Hepatitis C Treatment. U.S: Department of Veterans Affairs; 2007.
30.
go back to reference Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, et al. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14:74.CrossRefPubMedPubMedCentral Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, et al. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14:74.CrossRefPubMedPubMedCentral
31.
go back to reference Zeremski M, Zavala R, Dimova RB, Chen Y, Kritz S, Sylvester C, et al. Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. J Addict Med. 2016;10(2):102–7.CrossRef Zeremski M, Zavala R, Dimova RB, Chen Y, Kritz S, Sylvester C, et al. Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. J Addict Med. 2016;10(2):102–7.CrossRef
32.
go back to reference Strauss SM, Astone-Twerell J, Munoz-Plaza CE, Des Jarlais DC, Gwadz M, Hagan H, et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res. 2007;7:39.CrossRefPubMedPubMedCentral Strauss SM, Astone-Twerell J, Munoz-Plaza CE, Des Jarlais DC, Gwadz M, Hagan H, et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res. 2007;7:39.CrossRefPubMedPubMedCentral
33.
go back to reference Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55(6):1652–61.CrossRefPubMedPubMedCentral Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55(6):1652–61.CrossRefPubMedPubMedCentral
34.
go back to reference Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61.CrossRefPubMed Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61.CrossRefPubMed
36.
37.
go back to reference Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.CrossRefPubMedPubMedCentral Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.CrossRefPubMedPubMedCentral
38.
go back to reference Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34–59.CrossRefPubMed Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34–59.CrossRefPubMed
39.
go back to reference Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60–89.CrossRefPubMed Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60–89.CrossRefPubMed
40.
go back to reference Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr. 2004;37(3):1367–75.CrossRefPubMed Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr. 2004;37(3):1367–75.CrossRefPubMed
41.
go back to reference Mravcik V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence. 2013;7:1067–75.CrossRefPubMedPubMedCentral Mravcik V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence. 2013;7:1067–75.CrossRefPubMedPubMedCentral
42.
go back to reference Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol. 2013;12(3):380–91.PubMed Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol. 2013;12(3):380–91.PubMed
43.
44.
go back to reference Rosenberg WM, Tanwar S, Trembling P. Complexities of HCV management in the new era of direct-acting antiviral agents. QJM. 2014;107(1):17–9.CrossRefPubMed Rosenberg WM, Tanwar S, Trembling P. Complexities of HCV management in the new era of direct-acting antiviral agents. QJM. 2014;107(1):17–9.CrossRefPubMed
45.
go back to reference Strauss E. Barriers to care of chronic hepatitis patients in Latin America. Arch Med Res. 2007;38(6):711–5.CrossRefPubMed Strauss E. Barriers to care of chronic hepatitis patients in Latin America. Arch Med Res. 2007;38(6):711–5.CrossRefPubMed
46.
go back to reference Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol. 2013;11(8):922–33.CrossRefPubMed Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol. 2013;11(8):922–33.CrossRefPubMed
48.
go back to reference Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18(10):835–44.CrossRefPubMedPubMedCentral Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18(10):835–44.CrossRefPubMedPubMedCentral
Metadata
Title
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care
Authors
Rui Tato Marinho
António Costa
Teodomiro Pires
Helena Raposo
Carlos Vasconcelos
Cristina Polónia
Joaquim Borges
Mariana Soares
Graça Vilar
Ana Maria Nogueira
on behalf of the LIGUE-C Investigators
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1883-6

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue